# A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer

Source: https://onco.cc/trials/nct05939661/  
OnCo record `nct05939661` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Osaka University, now recruiting.

## Summary

A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer is a phase 2, interventional study registered as NCT05939661 by Osaka University, with a registry enrolment figure of 45 participants, started 2023-05-25 and due to reach its primary completion in 2026-03-31. Interventions recorded: Radiation; Chemotherapy; Surgery. Conditions listed: Rectal Cancer. Primary outcome: Pathological complete response (pCR). Colorectal eligibility wording from the registry: "The patient has adenocarcinoma of the rectum confirmed by histological examination". Sites: Japan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: AMBITION
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05939661
- Phase: 2
- Setting: A Multicenter Single-arm Phase 2 Study to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy of Short Course Radiation Therapy Followed by Neoadjuvant Oxaliplatin/Fluorouracil-based Chemotherapy (CAPOX) for cT2 Rectal Cancer.
- Sponsor: Osaka University
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT05939661: https://clinicaltrials.gov/study/NCT05939661

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05939661.json